Home・Aandelen Lijst・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Gesloten

SectorGezondheidszorg

35.19 -1.98

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

34.7

Max

35.2

Belangrijke statistieken
By Trading Economics
Inkomsten	10M 32M
Verkoop	-28M 215M
K/W Sectorgemiddelde	14.233 64.641
EPS	0.79
Winstmarge	15.084
Werknemers	293
EBITDA	-2.8M 49M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+15.95% upside

Dividenden
By Acuity
Volgende Winsten	4 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	199M 2.1B
Vorige openingsprijs	37.17
Vorige sluitingsprijs	35.19

Nieuwssentiment

By Acuity

34%

66%

92 / 340 Rangschikking in Healthcare

Harmony Biosciences Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 aug 2026, 00:01 UTC

Shares of Harmony Biosciences Holdings Inc are higher in after-market trading, reflecting notable strength since Friday's close without any specific news driving the move.

31 jul 2026, 23:21 UTC

Harmony Biosciences Holdings Inc. is trading higher during after-market hours, reflecting steady price increases since Friday's close, despite no specific news identified.

28 jul 2026, 18:26 UTC

News

Shares of Harmony Biosciences are lower despite a 30% revenue increase for WAKIX, as market sentiment reflects concerns over potential cash flow erosion.

27 jul 2026, 19:41 UTC

Shares of Harmony Biosciences Holdings Inc. are higher today, breaking from a recent upward trend despite the absence of specific company news.

24 jul 2026, 17:06 UTC

Shares of Harmony Biosciences Holdings Inc. are lower today, continuing a decline since Thursday's close, despite earlier reaching a session high.

22 jul 2026, 20:01 UTC

News

Harmony Biosciences Holdings Inc is trading lower despite preliminary Q2 2026 results showing record net product revenue of approximately $261 million, a 30% year-over-year increase.

21 jul 2026, 21:01 UTC

Harmony Biosciences Holdings Inc. shares are lower in after-market trading, diverging from a broader market rebound despite no specific news driving the decline.

Peer Vergelijking

Prijswijziging

Harmony Biosciences Holdings Inc Prognose

Koersdoel

By TipRanks

15.95% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 40.86 USD 15.95%

Hoogste 55 USD

Laagste 29 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Harmony Biosciences Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

Buy

Hold

Sell

Gebaseerd op 7 analisten die aandelenratings hebben gegeven aan Harmony Biosciences Holdings Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

92 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.